SGPL1 and multiple sclerosis: SPL, as key enzyme at the exit gate of the S1P degradation pathway, is considered an important drug target to modulate the levels of S1P in a variety of human diseases related to autoimmunity and inflammation including multiple sclerosis and rheumatoid arthritis20,61.